Prices delayed by at least 15 minutes | Print
Citius Pharmaceuticals (CTXR)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for thetreatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Address
11 Commerce Drive
First Floor
Cranford
NJ
USA
07016
Telephone
+1 908 967-6677
Forecast key dates
Name | Key Date |
---|---|
Citius Pharmaceuticals Inc Annual General Meeting for 2024 | 2025-03-12T00:00:00 |
Citius Pharmaceuticals Inc First Quarter Earnings Results for 2025 | 2025-02-14T00:00:00 |
Citius Pharmaceuticals Inc Annual Report for 2024 | 2024-12-27T00:00:00 |
Citius Pharmaceuticals Inc Third Quarter Earnings Results for 2024 | 2024-08-14T00:00:00 |
Citius Pharmaceuticals Inc Second Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Citius Pharmaceuticals Inc Second Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
Sidoti Small-Cap Virtual Conference | 2024-03-13T13:45:00 |
Citius Pharmaceuticals Inc Annual General Meeting for 2023 | 2024-03-12T00:00:00 |
BIO CEO and Investor Conference | 2024-02-27T09:45:00 |
Citius Pharmaceuticals Inc First Quarter Earnings Results for 2024 | 2024-02-14T00:00:00 |
Citius Pharmaceuticals Inc Annual Report for 2023 | 2023-12-29T00:00:00 |
Citius Pharmaceuticals Inc Third Quarter Earnings Results for 2023 | 2023-08-14T00:00:00 |
Citius Pharmaceuticals Inc Second Quarter Earnings Results for 2023 | 2023-05-12T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.